ProQR Therapeutics (NASDAQ:PRQR) Earns Market Outperform Rating from JMP Securities

ProQR Therapeutics (NASDAQ:PRQRGet Free Report)‘s stock had its “market outperform” rating reiterated by equities research analysts at JMP Securities in a research note issued on Friday,Benzinga reports. They currently have a $8.00 price target on the biopharmaceutical company’s stock. JMP Securities’ price objective suggests a potential upside of 292.16% from the company’s current price.

Several other brokerages have also recently issued reports on PRQR. Citigroup upgraded shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 target price on the stock in a report on Monday, March 10th. Oppenheimer dropped their target price on shares of ProQR Therapeutics from $15.00 to $9.00 and set an “outperform” rating on the stock in a report on Tuesday, May 13th. Cantor Fitzgerald started coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They set an “overweight” rating and a $8.00 target price on the stock. HC Wainwright increased their target price on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, March 14th. Finally, Chardan Capital reiterated a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a report on Friday, March 14th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, ProQR Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Read Our Latest Stock Report on PRQR

ProQR Therapeutics Price Performance

PRQR stock opened at $2.04 on Friday. ProQR Therapeutics has a 12 month low of $1.07 and a 12 month high of $4.62. The firm’s 50-day moving average is $1.74 and its 200 day moving average is $1.96. The company has a market capitalization of $214.63 million, a PE ratio of -5.83 and a beta of 0.31.

ProQR Therapeutics (NASDAQ:PRQRGet Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). ProQR Therapeutics had a negative return on equity of 53.49% and a negative net margin of 157.04%. The business had revenue of $4.89 million for the quarter, compared to the consensus estimate of $4.90 million. Sell-side analysts forecast that ProQR Therapeutics will post -0.31 EPS for the current fiscal year.

Institutional Trading of ProQR Therapeutics

A number of institutional investors have recently modified their holdings of PRQR. Jane Street Group LLC bought a new stake in shares of ProQR Therapeutics in the 4th quarter valued at about $30,000. Invesco Ltd. bought a new stake in shares of ProQR Therapeutics in the 4th quarter valued at about $32,000. Alpine Global Management LLC acquired a new stake in ProQR Therapeutics in the 4th quarter worth approximately $39,000. Two Sigma Securities LLC acquired a new stake in ProQR Therapeutics in the 4th quarter worth approximately $40,000. Finally, Vontobel Holding Ltd. acquired a new stake in ProQR Therapeutics in the 1st quarter worth approximately $48,000. 32.65% of the stock is currently owned by institutional investors.

About ProQR Therapeutics

(Get Free Report)

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

Further Reading

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.